Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telix Pharmaceuticals ( (AU:TLX) ) has shared an update.
Telix Pharmaceuticals Limited has notified the market of the issuance of an additional tranche of unquoted convertible notes. The company will issue 3,000 convertible notes, due on 22 April 2031, with the notes recorded as being issued on 22 April 2026.
The move adds to Telix’s mix of funding instruments and may support its longer-term capital management and development plans. By using unquoted convertible notes, Telix can potentially access capital while managing equity dilution over time, which is relevant for existing shareholders and prospective investors.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company listed on the ASX under the code TLX. The company operates in the pharmaceuticals sector, with a focus likely on specialty or advanced therapies, aiming to develop and commercialize medical products for targeted markets.
Average Trading Volume: 3,270,011
Technical Sentiment Signal: Hold
Current Market Cap: A$5.01B
Learn more about TLX stock on TipRanks’ Stock Analysis page.